With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older men, the importance of appropriate treatment and favorable outcomes is imperative. In this study we examine whether prostate cancer outcomes, such as risk category at diagnosis, treatment and survival differ in relationship to insurance status in older patients in CaPSURE. Data were abstracted from CaPSURE, a longitudinal observational database of 13 124 men with prostate cancer. Men were selected for the study if they were older than 65 years old at diagnosis, newly diagnosed between 1995 and 2005 at entry to CaPSURE with localized disease and received radical prostatectomy (RP), external beam radiation (EBRT), brachytherapy (BT), hormonal therapy or expectant management (EM). Insurance status was summarized by eight categories: Medicare only, Medicare þ supplement, Medicare þ HMO, Medicare þ PPO, Medicare þ FFS, health maintenance organization (HMO), preferred provider organization (PPO) and Veteran's Administration (VA). A total of 2983 men met the inclusion criteria. Odds ratios (OR) for the likelihood of receiving each type of therapy compared to RP by insurance status and likelihood of presenting with high-risk classification at diagnosis were derived using multinomial logistic regression, adjusting for clinical and demographic characteristics. Difference in survival between insurance groups was evaluated by Cox's multivariate regression. Multivariate analysis demonstrated a strong association between initial treatment and insurance status. Compared to Medicare patients, men in the CaPSURE database treated at HMO, PPO and VA systems were more likely to receive BT than RP (OR, 1.71-1.92) and less likely to receive this treatment if they were in Medicare þ FFS and Medicare þ PPO (OR, 0.18-0.38). Hormonal treatment demonstrated similar pattern, however OR did not reached statistical significance for HMO and PPO. Use of EM was much more predominant for patients in VA system (OR, 4.74; 95% CI, 1.94-11.55). Use of EBRT was significantly associated with type of insurance. Men with VA, Medicare þ FFS and Medicare þ PPO insurance were less likely to receive this treatment compared to RP. Survival and clinical risk at diagnosis was associated with insurance status in univariate analysis but this association diminished after adjusting for possible covariates. This study provides important information on relationship between insurance status and several outcomes in patients with prostate cancer. Even after controlling for important clinical and sociodemographic factors we found marked differences in prostate cancer treatment according to type of insurance. Future explorations of associations between health care delivery system, cancer care and outcomes are needed.
Introduction
With advent of growing numbers of 'baby boomers' reaching 65 years old in United States and increasing complexity of Medicare and other types of insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment interventions for cancer.
Insurance status is an important component in receiving education and counseling services, detection and screening activities, as well as receiving specific treatments, thus spanning the whole continuum of cancer care. [1] [2] [3] The importance of evaluation of the differences in outcomes between Medicare beneficiaries has been prompted by expanded use of managed care by Medicare; however, evaluation of outcomes in patients who have other types of insurances that are outside of the Medicare spectrum needs to be explored as well. Medicare is a federally funded public health insurance program designed for elderly (465 years) and permanently disabled. In 2003 over 40 millions of Americans were Medicare beneficiaries. 4 Prostate cancer is the most common noncutaneous cancer in men in the United States with estimated 230 900 new cases of prostate cancer identified in the United States in 2005 and leading cause of cancer death in men. 5 Treatment recommendations are generally based on guidelines established by the several organizations, such as National Comprehensive Cancer Network, ASCO and AUA, which take into consideration a patient's age and life expectancy, stage at diagnosis, comorbid illnesses and preferences based on side-effects and long-term outcomes. [6] [7] [8] [9] Studies that examined association between insurance status and outcomes such as types of treatment and survival in cancer demonstrated mixed results. In the study by Harlan et al., 10 receipt of guideline therapy for numerous cancers was lower then expected, particularly in patients with Medicaid or Medicare only, however the use of guideline therapy was not associated with insurance type in ovarian, cervical and rectal cancer. Conversely, the study by Wu et al. 11 did not find an insurance status to be associated with treatment patterns for stage III colon cancer. In the study by Kelz et al., 12 patients with colorectal carcinoma without private insurance had higher rates of complications and death compared to patients with private insurance. The survival and late-stage presentation at diagnosis of the patients with breast and lung cancer has been shown to be associated with several socioeconomic characteristics, such as living in more disadvantage areas, treatment in rural hospital but not directly associated with insurance status in the study by Hall et al.
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Differences in utilization of specific treatment modalities and survival in prostate cancer due to insurance status have been reported previously.
14-17 Potosky et al.
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used data from HMO and FFS Medicare patients diagnosed with prostate cancer between 1985 and 1992 and concluded that HMO patients were more likely to receive aggressive or definitive therapy then patients in FFS groups, however no significant differences in 10 years survival were found. The study by Wu et al.
17
examining patterns of treatment for prostate cancer in Louisiana between 1997 and 2001 and found that white, older patients with private insurance were more likely to receive more aggressive treatment (radical prostatectomy, RP or radiation) than other patients in the study. However, most studies have concentrated on comparisons of several subsets of insurance categories or combined them into overly broad categories that obscured important nuances of the relationship between insurance status, clinical and treatment characteristic and cancer outcomes. The current study examines whether, in a geographically diverse group of mostly community-based patients not limited to any type of treatments or types of health coverage, prostate-cancer risk category at diagnosis, type of treatment and survival in men older than 65 years differ in relationship to insurance status. We selected these factors as a surrogate measure of access and quality of care for patients diagnosed with prostate cancer. Specifically, using data from CaPSURE, we wished to test the hypothesis that, after controlling for baseline clinical and other socioeconomic characteristics, insurance status adds important predictive information about use of specific treatment modalities and survival for localized prostate cancer. The CaPSURE sample represents a broad geographic, practice and insurance-status spectrum, making results from this study applicable to a wider range of patients undergoing treatment for prostate cancer than results from primarily academic patient series.
Materials and methods

Outcomes measured
Pretreatment clinical stage, Gleason grade and prostatespecific antigen (PSA) level were combined into prostatecancer risk categories as described by D'Amico et al. [15] low risk (stage T1 or 2a, Gleason's score less than 7, PSA level less than 10 ng/ml), intermediate risk (stage T2b or Gleason's score 7 or PSA between 10 and 20 ng/ml) and high risk (any stage greater than T2b, Gleason's score greater than 7, PSA level greater then 20 ng/ml). Patients were grouped according to the number of comorbidities at enrollment into three categories, as follows: none, 1-3 and 3-5, with age at diagnosis defined by two categories (65-70 and 470 years old). We also included in our model sociodemographic variables found in other studies to be related to treatment type and insurance status: level of education defined by two groups (high school or less and greater than high school), income defined by two categories (o$50 000 and X$50 000 a year) and relationship status defined by two categories (single or in relationship).
Methods
Differences in clinical and sociodemographic characteristics by insurance groups were evaluated by w 2 analysis for categorical and ANOVA for continuous variables.
Association of clinical presentation (analysis 1), initial treatment (analysis 2) and insurance status was evaluated by multivariate regressions. Clinical risk as well as initial treatment has multiple possible categories; thus, we fit a multinomial logistic regression model. In multinomial regression, one outcome category serves as the referent for the others. In this analysis the low-risk group for the analysis 1 and RP for analysis 2 were used as a referent category because these were the most prominent categories and would provide the most statistical power. For the analysis 1 insurance status, age at diagnosis, number of comorbidities, household income, relationship status, race/ethnicity, education status and year of diagnosis were included. Similar set of variables was used for analysis 2 with addition of clinical risk categories and deletion of number of comorbidities. Insurance status was forced into the model at the start of the forward regression procedure. Because use of the treatments has changed over the time period of this analysis [13] , diagnosis year was also forced into the model a priori. Forward stepwise selection was performed to determine which variables were statistically related to clinical presentation, taking into Prostate cancer outcomes insurance status N Sadetsky et al account the other variables already in the model. The stay criterion for the forward-selection procedure was set at Po0.05. Odds ratios (OR) for the likelihood of presenting at each clinical risk category compared with low risk, and likelihood of receiving specific treatment compared to RP were derived adjusting for clinical and demographic characteristics.
The hazards ratios of the probability of dying by insurance group compared with Medicare only, were estimated using the Cox's proportional hazard model. Due to the smaller number of events, insurance categories were collapsed into five groups: Medicare only, Medicare þ supplement, HMO, PPO and VA. Models were adjusted for clinical risk, type of initial treatment, number of comorbidities and age at diagnosis.
All analyses were performed using version 9.1 of SAS with the Windows operating system (SAS Institute, Cary, NC, USA).
Results
Of the 13 124 patients enrolled in CaPSURE at June 2006, 2507 patients were newly diagnosed with localized prostate cancer, treated between 1995 and 2006, were older than 65 years of age, and had complete sociodemographic information. The sociodemographic and clinical characteristics of the study cohort and distribution of insurance types are presented in Table 1 . More than half of the study population was in Medicare and Medicare þ Supplement group (22.3 and 44.2%, respectively). Medicare with supplemental insurance defined by PPO, HMO and FFS constituted another 15% (6.5, 3.03 and 5.9%, respectively) with remainder of the patients in HMO, PPO and VA (see Table 1 ). About one-third of the patients in the study population (34.5%) underwent RP as an initial treatment, with remainder of the treatment distributed among brachytherapy (BT), hormonal therapy (HT), external beam radiation (EBRT) and expectant management (EM) (see Table 1 ). Significant differences in sociodemographic characteristics existed between patients in different insurance groups.
In the univariate analysis, patients in the VA were more likely to present at diagnosis with a high-risk than low-risk (OR, 1.89; 95% CI, 1.02-3.52; P-value 0.04) classification compared with Medicare, while the patients in HMOs, PPOs, Medicare þ supp, Medicare þ PPO and Medicare þ FFS were less likely to present with high risk at diagnosis than patients with Medicare (OR range, 0.6-0.7; however, only HMO patients reached statistical significance at OR, 0.61; 95% CI, 0.41-0.89). Risk classification was also significantly associated with age, year of diagnosis, race and education. In the multivariable analysis, after adjustment for possible covariates, effect of insurance diminished; however, the pattern of association stayed the same (see Table 2 ).
After adjusting for clinical risk status, age, level of education, household income, marital status, number of comorbidities at baseline, race/ethnicity and year of diagnosis, insurance type remained statistically significantly associated with type of treatment received in the multinomial logistic regression (P ¼ 0.001). The specific OR comparing the use of each initial treatment with RP for the different types of insurance are shown in Table 3 .
Compared with Medicare patients, men treated at HMOs, PPOs and the VA were more likely to receive BT than RP (OR, 1.71-1.92) and less likely to receive this treatment if they were in Medicare þ FFS and Medicare þ PPO (OR, 0.18-0.38). HT demonstrated a similar pattern; however, OR did not reach statistical significance for HMOs and PPOs. Use of EM was much more predominant for patients in the VA system (OR, 4.74; 95% CI, 1.94-11.55). Use of EBRT was significantly associated with type of insurance. Men treated in the VA, Medicare þ FFS and Medicare þ PPO systems were less likely to receive this treatment than RP.
During the mean follow-up of 3.2 years (range, 1.6-4.4 years), there were 259 (10.3%) deaths among study subjects, with 33 (14.7%) due to prostate cancer. Even though the previous analysis of CaPSURE that included patients of all ages and broader categories of insurance (combination of PPO/HMO and combination of all Medicare þ supp) insurance was associated with survival, present analysis did not confirm those results. 15 In the univariate analysis, overall survival was associated with insurance status (P-value 0.03), with patients in VA more likely to die than patients with Medicare only (hazard ratio, 2.1; 95% CI, 1.2-3.1). After adjustment for possible covariates, such as type of treatment, clinical risk category, number of comorbidities and age at diagnosis, the effect diminished; but we continue to see the same pattern (see Table 4 ).
Discussion
This study presents comprehensive approach in evaluation of an association of the several outcomes of prostate cancer care with type of insurance in older patients. The results of this study suggest that choice of primary treatment in newly diagnosed older patients with prostate cancer may be influenced not only by clinical tumor characteristics (such as stage at diagnosis, PSA levels and histopathologic differences) but also by insurance status. The relationship between insurance status and other outcomes such as risk classification at diagnosis and all-cause mortality were also explored.
In general, patients in HMO, PPO and VA were more likely to receive brachytherapy and hormonal treatment than RP when compared to Medicare only. In contrast, patients in Medicare þ FFS and Medicare þ PPO were less likely to receive those treatments, in addition to lower likelihood of receiving EXRT. The utilization of EM was much higher in patients in VA and much lower for patients in Medicare þ FFS and Medicare þ PPO. Clinical risk at diagnosis and survival were associated with insurance status in univariate analysis with patients in VA demonstrating worse survival and greater likelihood of presenting with high-risk category at diagnosis, however this relationship was diminished after adjustment for possible covariates.
In the study by Potosky et al. 15 men received surgery twice as often if they had FFS insurance vs HMO insurance, while radiation therapy was more prevalent in men enrolled in an HMO. Use of aggressive therapy (that is, surgery or radiation) was associated with younger age, white race, higher education moderate or high grade tumors and lower comorbidity. In our study The relationship between socioeconomic status and initial treatment for men with prostate cancer has been described previously.
14,19-21 Morris et al. concluded that regardless of the stage at diagnosis, men who were younger and had higher income and education levels were most likely to receive more aggressive treatment such as RP. Our study indicated that significant relationship between sociodemographic characteristics of the patients and receipt of specific treatment existed as well, however even after adjusting for income and education relationship with insurance remained, thus suggesting independent effect of insurance on receipt of treatment.
Strong association of worse outcomes such as survival and later-stage diagnosis with being uninsured have been demonstrated in many studies, however we were unable to make this comparison due to small numbers of patients with Medicaid or no insurance in our study. 16, 17, 21 Patients in VA demonstrated worse survival and presentation at later stage at diagnosis, though previous studies of the VA population in CaPSURE concluded that such patients are more likely to be nonwhite, have lower income and education, and higher risk disease. 22 The reasons why insurance status plays a role in receipt of specific treatments remained uncertain. It has been proposed that insurance influence receipt of appropriate heath care through several mechanisms, such as obtaining services in timely fashion, getting services appropriate for patients needs and ability to access continuity of care. 1 In addition, this relationship could be influenced by interaction between factors involving patients, health care providers and systems of care. Results from descriptive studies such as ours, could provide some insights regarding factors associated with those interactions.
The findings of this study could have some policy implications. With increasing involvement of managed care in Medicare administration, comparisons of outcomes between different modes of administration could give us an important insight into course of disease. In our study, receipt of specific treatment did not differ between Medicare only and Medicare þ supplement, thus suggesting that those types of insurance provide comparable care for the patients with similar characteristic. At the same time similarity in presentation at diagnosis between patients in different insurance groups provide some evidence to widespread screening.
There are several limitations to our study. Having very few patients without insurance or with Medicaid insurance limited our ability to explore utilization of different treatment modalities in such groups. The nature of the observational study prevented us from fully accounting for some types of patient's characteristics that could have influenced selection into different insurances types as well as type of treatment. We were not able to evaluate patient's role in the decision-making process that could have lead to specific treatments due to the absence of information on patient's preferences in our study. In addition, this cohort of men is not a random sample, thus cannot be representative of general population of the United States. This complicates the generalizability of current results.
While recognizing these limitations, this study has many advantages as well. Men in the CaPSURE database represent a geographically diverse group of mostly community-based patients in order to reflect treatment in the field. The large number of men included in this analysis allowed for examination of variety of types of insurance (rather than just HMO vs FFS) and for specific treatments, rather than lumping treatments into surgical vs nonsurgical or aggressive vs nonaggressive treatment groups. The evaluation of several outcomes, such as clinical stage at diagnosis and survival in addition to type of treatment provide us with comprehensive evaluation of the role of insurance in prostate cancer care continuum.
In conclusion, this study found that an insurance status was a significant determinant of receipt of different types of initial treatment for prostate cancer in older patients in cancer, although it had lesser effect on stage at diagnosis and survival. Insurance is an important component of access to cancer preventive, diagnostic and treatment services. Examination of those relationships can provide us with important insights in Prostate cancer outcomes insurance status N Sadetsky et al Unadjusted and adjusted hazard ratios and 95% confidence intervals for probability of dying for different insurance groups relative to Medicare only. *Statistically significant at P-value o0.05.
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